Sensus Healthcare Reports 68.5% Revenue Decline in Q2 2026

Sensus Healthcare, Inc. reported a significant decline in financial performance for the second quarter of 2026, with revenues dropping to $2.3 million, a decrease of 68.5% compared to $7.3 million in the same period last year. For the first half of 2026, total revenues were $5.7 million, down 63.7% from $15.7 million in the first half of 2025. The company attributed this decline primarily to a reduced number of units sold, with only six units sold in the second quarter of 2026 compared to 19 in the same quarter of 2025. Additionally, some sales were made under the Fair Deal Agreement program, which defers revenue recognition over the term of the agreement rather than at the time of shipment.

The company's cost of sales also decreased, amounting to $1.5 million for the second quarter of 2026, down 65.9% from $4.4 million in the prior year. Gross profit for the quarter was $769,000, a 72.4% decline from $2.9 million in the same quarter of 2025. The gross profit margin fell to 34.8% from 39.7%, influenced by a shift in product mix and costs associated with new system placements under the Fair Deal Agreements. Operating expenses totaled $3.9 million for the second quarter, down from $4.8 million a year earlier, reflecting reductions in general and administrative, selling and marketing, and research and development expenses.

Sensus Healthcare's net loss for the second quarter was $8.7 million, compared to a loss of $1.0 million in the same period last year. The loss per share was $(0.53) for the quarter, compared to $(0.06) in the prior year. The increase in net loss was partly due to a valuation allowance against deferred tax assets, which significantly impacted the effective tax rate, resulting in an effective tax rate of (185.6%) for the quarter.

In terms of operational developments, Sensus Healthcare's cash, restricted cash, and cash equivalents decreased to $15.2 million as of June 30, 2026, from $22.1 million at the end of 2025. Accounts receivable also fell to $1.7 million, down from $6.0 million, while inventories increased to $18.5 million, reflecting expectations of future sales. The company has not reported any borrowings under its revolving credit facility as of June 30, 2026, following the termination of a previous credit facility in May 2026.

Looking ahead, Sensus Healthcare remains focused on its strategic initiatives, including the expansion of its Fair Deal Agreement program and efforts to enhance product offerings. The company is committed to evaluating its liquidity and capital resources to support ongoing operations and potential growth opportunities. However, management acknowledges that future performance may be influenced by market conditions, customer demand, and the ability to generate revenue from its product lines.